Context Therapeutics (CNTX) Competitors $1.63 -0.02 (-1.21%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CNTX vs. UNCY, MTCR, MREO, ARCT, ALMS, YMAB, ZVRA, ESPR, RGNX, and SLRNShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Unicycive Therapeutics (UNCY), Metacrine (MTCR), Mereo BioPharma Group (MREO), Arcturus Therapeutics (ARCT), Alumis (ALMS), Y-mAbs Therapeutics (YMAB), Zevra Therapeutics (ZVRA), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), and Acelyrin (SLRN). These companies are all part of the "medical" sector. Context Therapeutics vs. Unicycive Therapeutics Metacrine Mereo BioPharma Group Arcturus Therapeutics Alumis Y-mAbs Therapeutics Zevra Therapeutics Esperion Therapeutics REGENXBIO Acelyrin Context Therapeutics (NASDAQ:CNTX) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability. Does the media refer more to CNTX or UNCY? In the previous week, Unicycive Therapeutics had 15 more articles in the media than Context Therapeutics. MarketBeat recorded 15 mentions for Unicycive Therapeutics and 0 mentions for Context Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.80 beat Context Therapeutics' score of -0.50 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Context Therapeutics Negative Unicycive Therapeutics Positive Is CNTX or UNCY more profitable? Unicycive Therapeutics' return on equity of 0.00% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Context TherapeuticsN/A -58.76% -55.80% Unicycive Therapeutics N/A N/A -29.88% Which has better earnings and valuation, CNTX or UNCY? Context Therapeutics has higher earnings, but lower revenue than Unicycive Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContext TherapeuticsN/AN/A-$23.96M-$0.91-1.79Unicycive Therapeutics$680K77.76-$30.54M-$0.97-0.53 Do analysts rate CNTX or UNCY? Context Therapeutics currently has a consensus target price of $6.25, suggesting a potential upside of 283.44%. Unicycive Therapeutics has a consensus target price of $5.13, suggesting a potential upside of 906.09%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Context Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more volatility and risk, CNTX or UNCY? Context Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Do institutionals and insiders hold more shares of CNTX or UNCY? 14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 3.0% of Context Therapeutics shares are owned by company insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community believe in CNTX or UNCY? Unicycive Therapeutics received 12 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 74.36% of users gave Unicycive Therapeutics an outperform vote while only 70.83% of users gave Context Therapeutics an outperform vote. CompanyUnderperformOutperformContext TherapeuticsOutperform Votes1770.83% Underperform Votes729.17% Unicycive TherapeuticsOutperform Votes2974.36% Underperform Votes1025.64% SummaryUnicycive Therapeutics beats Context Therapeutics on 14 of the 16 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$123.75M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-1.794.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book1.4610.126.936.25Net Income-$23.96M$153.61M$119.12M$225.93M7 Day Performance-14.21%-2.00%-1.83%-1.32%1 Month Performance-20.87%-7.47%-3.64%0.60%1 Year Performance101.23%31.80%31.64%26.23% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics2.0666 of 5 stars$1.63-1.2%$6.25+283.4%+81.1%$123.75MN/A-1.797UNCYUnicycive Therapeutics3.4448 of 5 stars$0.51+4.1%$5.13+906.1%-2.0%$50.34M$680,000.000.009Analyst RevisionMTCRMetacrineN/A$0.58flatN/A+0.0%$24.75MN/A-0.5610MREOMereo BioPharma Group2.9665 of 5 stars$3.58+2.6%$7.50+109.5%+63.5%$489.50M$10M0.0040Analyst RevisionNews CoverageARCTArcturus Therapeutics2.0511 of 5 stars$16.17-10.5%$71.40+341.6%-33.7%$489.20M$169.93M-7.28180ALMSAlumisN/A$9.64-6.9%$26.83+178.4%N/A$488.75MN/A0.00N/AAnalyst RevisionHigh Trading VolumeYMABY-mAbs Therapeutics3.3273 of 5 stars$10.54-2.9%$21.38+102.8%+100.8%$486.41M$84.82M0.00150Analyst ForecastZVRAZevra Therapeutics3.4632 of 5 stars$8.97flat$21.00+134.1%+100.2%$478.78M$27.46M-4.5565Analyst ForecastAnalyst RevisionESPREsperion Therapeutics3.9536 of 5 stars$2.41flat$8.17+238.9%+97.5%$474.86M$116.33M-3.77240Analyst ForecastRGNXREGENXBIO4.4242 of 5 stars$9.63+0.7%$35.64+270.1%-51.9%$473.65M$90.24M-1.91344Analyst ForecastAnalyst RevisionSLRNAcelyrin3.3895 of 5 stars$4.43-6.1%$11.50+159.6%-50.2%$473.54MN/A-1.80135Analyst RevisionPositive News Related Companies and Tools Related Companies UNCY Alternatives MTCR Alternatives MREO Alternatives ARCT Alternatives ALMS Alternatives YMAB Alternatives ZVRA Alternatives ESPR Alternatives RGNX Alternatives SLRN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTX Stock Alerts